GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Rigel Pharmaceuticals Inc (FRA:RI2) » Definitions » Cyclically Adjusted PS Ratio

Rigel Pharmaceuticals (FRA:RI2) Cyclically Adjusted PS Ratio : 2.20 (As of Sep. 23, 2024)


View and export this data going back to . Start your Free Trial

What is Rigel Pharmaceuticals Cyclically Adjusted PS Ratio?

As of today (2024-09-23), Rigel Pharmaceuticals's current share price is €12.10. Rigel Pharmaceuticals's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2024 was €5.50. Rigel Pharmaceuticals's Cyclically Adjusted PS Ratio for today is 2.20.

The historical rank and industry rank for Rigel Pharmaceuticals's Cyclically Adjusted PS Ratio or its related term are showing as below:

FRA:RI2' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 1.33   Med: 3.29   Max: 14.79
Current: 2.35

During the past years, Rigel Pharmaceuticals's highest Cyclically Adjusted PS Ratio was 14.79. The lowest was 1.33. And the median was 3.29.

FRA:RI2's Cyclically Adjusted PS Ratio is ranked better than
70.11% of 465 companies
in the Biotechnology industry
Industry Median: 5.31 vs FRA:RI2: 2.35

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Rigel Pharmaceuticals's adjusted revenue per share data for the three months ended in Jun. 2024 was €1.950. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is €5.50 for the trailing ten years ended in Jun. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Rigel Pharmaceuticals Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Rigel Pharmaceuticals's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Rigel Pharmaceuticals Cyclically Adjusted PS Ratio Chart

Rigel Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.27 11.12 6.23 2.95 2.58

Rigel Pharmaceuticals Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.38 1.96 2.58 2.57 1.40

Competitive Comparison of Rigel Pharmaceuticals's Cyclically Adjusted PS Ratio

For the Biotechnology subindustry, Rigel Pharmaceuticals's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Rigel Pharmaceuticals's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Rigel Pharmaceuticals's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Rigel Pharmaceuticals's Cyclically Adjusted PS Ratio falls into.



Rigel Pharmaceuticals Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Rigel Pharmaceuticals's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=12.10/5.5
=2.20

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Rigel Pharmaceuticals's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2024 is calculated as:

For example, Rigel Pharmaceuticals's adjusted Revenue per Share data for the three months ended in Jun. 2024 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Jun. 2024 (Change)*Current CPI (Jun. 2024)
=1.95/132.5538*132.5538
=1.950

Current CPI (Jun. 2024) = 132.5538.

Rigel Pharmaceuticals Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201409 0.000 100.428 0.000
201412 0.000 99.070 0.000
201503 0.229 99.621 0.305
201506 0.524 100.684 0.690
201509 1.308 100.392 1.727
201512 0.880 99.792 1.169
201603 0.499 100.470 0.658
201606 0.827 101.688 1.078
201609 0.351 101.861 0.457
201612 0.287 101.863 0.373
201703 0.295 102.862 0.380
201706 0.000 103.349 0.000
201709 0.061 104.136 0.078
201712 0.000 104.011 0.000
201803 0.000 105.290 0.000
201806 0.095 106.317 0.118
201809 0.250 106.507 0.311
201812 1.996 105.998 2.496
201903 0.668 107.251 0.826
201906 0.551 108.070 0.676
201909 1.130 108.329 1.383
201912 0.827 108.420 1.011
202003 2.994 108.902 3.644
202006 0.844 108.767 1.029
202009 0.924 109.815 1.115
202012 0.897 109.897 1.082
202103 3.865 111.754 4.584
202106 1.281 114.631 1.481
202109 1.072 115.734 1.228
202112 1.056 117.630 1.190
202203 0.885 121.301 0.967
202206 1.639 125.017 1.738
202209 1.310 125.227 1.387
202212 2.800 125.222 2.964
202303 1.403 127.348 1.460
202306 1.430 128.729 1.472
202309 1.512 129.860 1.543
202312 1.882 129.419 1.928
202403 1.551 131.776 1.560
202406 1.950 132.554 1.950

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Rigel Pharmaceuticals  (FRA:RI2) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Rigel Pharmaceuticals Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Rigel Pharmaceuticals's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Rigel Pharmaceuticals Business Description

Traded in Other Exchanges
Address
611 Gateway Boulevard, Suite 900, South San Francisco, CA, USA, 94080
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's lead drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility to develop and market the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.

Rigel Pharmaceuticals Headlines

No Headlines